NCT Number: NCT06136650
Phase: PHASE3
Trial Summary: The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metast – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Merck Sharp & Dohme LLC
Acronym:
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives